Sonoma Bio, Engineering T-cell Therapies for Autoimmunity, Nabs $265M Series B

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

T Cell Therapies for Autoimmunity: Jeff Bluestone on The Long Run
Rivus Gets $35M to Alter Mitochondria for T2D, NASH, Heart Failure & More
F-Prime Leads $60M Bet on Adela, Scanning the Methylome for Early Signs of Cancer
CAR-T for Autoimmunity: Bluestone Joins Sonoma Biotherapeutics, a $40M Bet